Mili Arora, M.D.
Associate Professor (HSCP)
To see if Mili Arora is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
Hematology/Oncology Clinic
4501 X Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Arora believes in high quality, innovative, and compassionate care of her patients. She believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients. Dr. Arora utilizes investigational therapy for relevant clinical scenarios.
Clinical Interests
Dr. Arora’s clinical interests are in breast cancer, and endocrine cancers.
Research/Academic Interests
Dr. Arora's research focuses on improving the landscape of treatments for breast cancer. She has a specific interest in triple negative breast cancer and developing better supportive therapies to use adjunctively with standard breast cancer treatments.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.S., Virginia Commonwealth University, Richmond VA 2004
Medical School
M.D., George Washington University, Washington DC 2009
Residency
Internal Medicine, Tufts Medical Center, Boston MA 2009-2012
Fellowship
Hematology/Oncology, UC Davis Medical Center, Sacramento CA 2012-2015
Safeway Grant Recipient, 2020
Placer Breast Cancer Foundation award for research/trial work, 2019
Christine and Helen Landgraf Memorial Research Award recipient, 2019
Chief Fellow, UC Davis, 2014, 2015
For a comprehensive list of Dr. Arora's publications, please click here (opens new window).
Beechinor R, Palumbo A, Chew HK, Arora M. Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022 Feb;7(1):100393. doi:10.1016/j.esmoop.2022.100393. Epub 2022 Feb 4. Erratum in: ESMO Open. 2022 Mar 17;7(2):100460. PMID:35131650.
Semrad TJ, Kim EJ, Gong IY, Li T, Christensen S, Arora M, Riess JW, Gandara DR, Kelly K. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021 Aug;88(2):335-341. doi:10.1007/s00280-021-04293-3. Epub 2021 May 15. PMID:33993383.
Bateni SB, Perry LM, Zhao X, Arora M, Daly ME, Stewart SL, Bold RJ, Canter RJ, Sauder CAM. The Role of Radiation Therapy in Addition to Lumpectomy and Hormone Therapy in Men 70 Years of Age and Older with Early Breast Cancer: A NCDB Analysis. Ann Surg Oncol. 2021 May;28(5):2463-2471. doi:10.1245/s10434-020-09242-7. Epub 2020 Oct 22. PMID:33094375.
Poh C, Arora M, Ghuman S, Tuscano J. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Acta Haematol. 2021;144(1):95-99. doi:10.1159/000506918. Epub 2020 Apr 29. PMID:32348994.
Arora M, Meyers FJ. Homologous Recombination DNA Repair Gene Aberrations-Are We More Alike Than Different? JAMA Netw Open. 2020 Oct 1;3(10):e2021717. doi:10.1001/jamanetworkopen.2020.21717. PMID:33112396.
Sauder CAM, Li Q, Othieno A, Cruz D, Arora M, Bold RJ, Meyers FJ, Keegan THM. Characteristics and Outcomes for Secondary Breast Cancer in Childhood, Adolescent, and Young Adult Cancer Survivors Treated with Radiation. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1767-1774. doi:10.1158/1055-9965.EPI-20-0260. PMID:32847936.
Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):e291-294. doi:10.1002/ajh.25605. Epub 2019 Aug 20. PMID:31379016.
Bateni SB, Davidson AJ, Arora M, Daly ME, Stewart SL, Bold RJ, Canter RJ, Sauder CAM. Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis. Ann Surg Oncol. 2019 Jul;26(7):2144-2153. doi:10.1245/s10434-019-07159-4. Epub 2019 Feb 13. PMID:30761438.
Schwab E, Chen JA, Huynh JC, Ji J, Arora M, Cho M, Kim EJ. Rational Strategies for Combining Bcl-2 Inhibition with Targeted Drugs for Anti-Tumor Synergy. J Cancer Treatment Diagn. 2019;3(4):7-13.